COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 12 for:    midodrine | orthostatic hypotension | Phase 3, 4
Previous Study | Return to List | Next Study

Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01518946
Recruitment Status : Completed
First Posted : January 26, 2012
Results First Posted : July 31, 2014
Last Update Posted : January 9, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine whether midodrine works against the symptoms of orthostatic hypotension caused by being on a tilt table.

Condition or disease Intervention/treatment Phase
Orthostatic Hypotension Drug: Midodrine HCl Drug: Placebo Phase 4

Detailed Description:
The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 4 overnight stays.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension
Actual Study Start Date : May 14, 2012
Actual Primary Completion Date : June 22, 2013
Actual Study Completion Date : June 22, 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Midodrine HCl Drug: Midodrine HCl
dose at the subject's current dose level
Other Name: ProAmatine®

Placebo Comparator: Placebo Drug: Placebo
single dose of matching placebo

Primary Outcome Measures :
  1. Time to Onset of Syncope/Near Syncope While on Tilt Table [ Time Frame: 1 hour post-dose ]
    After a 30-minute supine period, the table was tilted from 0-90º within 30 seconds and maintained in that position for 45 minutes or until endpoint. Subjects were monitored for near-syncopal symptoms (subject felt sufficiently dizzy, lightheaded, faint, or felt like they were about to black out and requested the table to be returned to horizontal). Such a report ended the test. Alternatively, if the investigator observed that the subject was about to lose consciousness, that also constituted an endpoint.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects must be 18 years of age or older and ambulatory.
  2. Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.
  3. A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months.
  4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.

Exclusion Criteria:

  1. The subject is a pregnant or lactating female.
  2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.
  3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.
  4. The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant
  5. The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).
  6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.
  8. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.
  9. Prior enrollment failure or randomization in this study.
  10. History of alcohol abuse or other substance abuse within the last year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01518946

Layout table for location information
United States, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States, 33486
Advance Research Institute Inc
New Port Richey, Florida, United States, 34653
United States, Kansas
Analab Clinical Research Inc
Lenexa, Kansas, United States, 66219
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
Buffalo Clinical Research Center (BCRC)
Buffalo, New York, United States, 14202
NYU Medical Centre
New York, New York, United States, 10016
Columbia University
New York, New York, United States, 10032
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Oregon
Kidney and Hypertension Center
Roseburg, Oregon, United States, 97471
United States, Tennessee
New Orleans Center for Clinical Research - Knoxville
Knoxville, Tennessee, United States, 37920
United States, Texas
The Heartbeat Clinic, PA
McKinney, Texas, United States, 75069
United States, Utah
Aspen Clinical Research
Orem, Utah, United States, 84058
United States, Wisconsin
Aurora Cardiovascular Services
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Layout table for investigator information
Study Director: Study Director Shire
Publications of Results:
Layout table for additonal information
Responsible Party: Shire Identifier: NCT01518946    
Other Study ID Numbers: SPD426-406
First Posted: January 26, 2012    Key Record Dates
Results First Posted: July 31, 2014
Last Update Posted: January 9, 2019
Last Verified: December 2018
Keywords provided by Shire:
Symptomatic Orthostatic Hypotension
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypotension, Orthostatic
Orthostatic Intolerance
Vascular Diseases
Cardiovascular Diseases
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Vasoconstrictor Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action